Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Aclarion, Inc. ( (ACON) ) has issued an update.
On September 3, 2025, Aclarion, Inc. announced the appointment of Greg Gould as the new Chief Financial Officer, effective immediately. Gould, who brings over 30 years of experience in public and private companies, is expected to leverage his expertise in capital strategies and financial leadership to support Aclarion’s growth and the wider availability of its Nociscan platform, which aims to improve treatment for chronic low back pain.
The most recent analyst rating on (ACON) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Aclarion, Inc. stock, see the ACON Stock Forecast page.
More about Aclarion, Inc.
Aclarion, Inc. is a healthcare technology company that utilizes Magnetic Resonance Spectroscopy, proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to enhance clinical treatments. The company focuses on the chronic low back pain market with its Nociscan platform, which noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine.
Average Trading Volume: 13,225
Technical Sentiment Signal: Sell
Current Market Cap: $4.17M
See more insights into ACON stock on TipRanks’ Stock Analysis page.